the aid library

LIST OPTIONS

Filter

12302

Gestion des dépouilles mortelles lors de catastrophes : manuel pratique à l’usage des premiers intervenants. 2ième éd., rév.

Cordner, S.; Coninx, R.; Kim, J.-J. et al. (Éd.) Organisation mondiale de la santé (OMS), Organisation panaméricaine de la santé, Fédération internationale des Sociétés de la Croix-Rouge et du Croissant-Rouge (2016) C_WHO

La deuxième édition de ce manuel fournit des directives simples, concrètes et faciles à suivre pour la récupération et le stockage des corps des personnes décédées lors de catastrophes et l’enregistrement des informations les concernant, l’objectif étant d’aider les premiers interven... more

Download (709)

View PDF (1754)

Framework for a national plan for monitoring and management of insecticide resistance in malaria vectors

World Health Organization (WHO) (2017) C_WHO

Effective malaria prevention is threatened by widespread and increasing vector insecticide resistance. Failure to mitigate this threat will likely result in an increased burden of disease, with significant cost implications. This new framework provides support for the development of a national insec... more

Download (887)

View PDF (1901)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (446)

View PDF (547)

Planning, Monitoring and Evaluation. Webinar 14. Companion Technical Booklet

Mont, D. UNICEF (2014)

Download (524)

View PDF (738)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (398)

View PDF (414)

Manual for male circumcision under local anaesthesia and HIV prevention services for adolescent boys and men
recommended

World Health Organization WHO (2018) C_WHO

Download (18488)

View PDF (3017)

Paediatrics for Doctors in Papua New Guinea

Frank Shann and John Vince (2003)

A guide for doctors providing health services for children. 2nd edition

Download (2485)

View PDF (3098)

Combined course on growth assessment and IYCF counselling. Participant's Manual

World Health Organization (2012) C_WHO

Download (1412)

View PDF (3283)

Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India + Annexures

Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare (2012) C1

Download (1527)

View PDF (3891)

Birth defects surveillance: Atlas of selected congenital anomalies

World Health Organization (WHO), National Center on Birth Defects and Developmental Disabilities from the United States Centers for Disease Control and Prevention (CDC), International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) (2014) C_WHO

It provides selected illustrations and photographs of congenital anomalies that are severe enough to have a high probability of being captured during the first few days following birth

Download (353)

View PDF (297)

Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy

World Health Organization WHO (2022) C_WHO

WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi... more

Download (1141)

View PDF (1324)

Joint Government of the Repubic of Zambia and the United Nations Population Fund 2007 – 2010 Evaluation Report

Ministry of Finance and National Planning, Zambia (2010) C1

Download (2461)

View PDF (1502)

Guide de Counseling VIH/SIDA

Ministère de la Santè et de la Prévention, Senegal Programme National de Lutte contre le SIDA (2001) C1

Download (991)

View PDF (1413)

Additional Content to the National Sexually Transmitted Infections Care and Treatment Course for Health Care Workers

Dept. of Health, Republic of South Africa (2015) C1

High Transmission Areas: Key Populations

External Link

Une meilleure gestion des déchets d’activités de soins

Rushbrook, R.; Zghondi, R. OMS; Banque Mondiale (2005) C_WHO

Une composante intégrale de l’investissement dans la santé

Download (2281)

View PDF (2169)

WHO Safe Childbirth Checklist Implementation Guide
recommended

World Health Organization WHO (2015) C_WHO

This implementation guide has been developed to help birth attendants and health-care leaders successfully launch and sustain use of the WHO Safe Childbirth Checklist. Development, use and implementation of the Checklist are described in this guide. It covers how to introduce and ensure continuous ... more